Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$4.2 million.

  • Protalix BioTherapeutics' Free Cash Flow fell 20527.63% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.7 million, marking a year-over-year decrease of 26304.56%. This contributed to the annual value of $7.4 million for FY2024, which is 39963.52% up from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Free Cash Flow of -$4.2 million as of Q3 2025, which was down 20527.63% from -$5.5 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Free Cash Flow's 5-year high stood at $6.2 million during Q2 2021, with a 5-year trough of -$10.2 million in Q1 2021.
  • Over the past 5 years, Protalix BioTherapeutics' median Free Cash Flow value was -$3.8 million (recorded in 2024), while the average stood at -$2.5 million.
  • In the last 5 years, Protalix BioTherapeutics' Free Cash Flow tumbled by 31645.68% in 2022 and then soared by 21844.9% in 2023.
  • Protalix BioTherapeutics' Free Cash Flow (Quarter) stood at -$5.5 million in 2021, then soared by 48.98% to -$2.8 million in 2022, then soared by 218.45% to $3.3 million in 2023, then increased by 6.61% to $3.6 million in 2024, then crashed by 218.62% to -$4.2 million in 2025.
  • Its Free Cash Flow stands at -$4.2 million for Q3 2025, versus -$5.5 million for Q2 2025 and -$5.5 million for Q1 2025.